Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
Compounds
US8993560B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8993560-B2 |
| Application number | US-201213414873-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 8, 2012 |
| Priority date | Mar 11, 2011 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory diseases and/or allergic conditions, in cancer therapy, specifically heme malignancies, and autoimmune conditions.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound which is: 7-(2-(methyloxy)-6-{[(4-methyl-2-pyridinyl)methyl]oxyl phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; or a salt thereof. 2. The compound or salt according to claim 1 , wherein the salt is a pharmaceutically acceptable salt. 3. The compound or salt according to claim 1 , w…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8993560B2 cover?
- A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage,…
- Who is the assignee on this patent?
- Atkinson Francis Louis, Barker Michael David, Liddle John, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).